Fiona H. Marshall
President, Biomedical ResearchNovartis
PharmaceuticalsView Profile →EVP, Oncology Business Unit · AstraZeneca
David Fredrickson leads AstraZeneca’s Oncology Business Unit. His earlier work includes strategy consulting, commercial leadership at Roche and Genentech, and senior AstraZeneca assignments in the United States and Japan.
Last reviewed: Nov 16, 2026
David Fredrickson leads AstraZeneca’s Oncology Business Unit. His earlier work includes strategy consulting, commercial leadership at Roche and Genentech, and senior AstraZeneca assignments in the United States and Japan.
Fredrickson earned a Bachelor of Arts in government at Georgetown University and began his professional career in strategy consulting at Monitor Group, now part of Monitor Deloitte. He subsequently moved into the pharmaceutical industry at Roche and Genentech.
His commercial assignments included oncology business-unit management in Spain and strategy, marketing and sales work in the United States. He joined AstraZeneca in 2014, later becoming vice president for Specialty Care in the United States and president of AstraZeneca K.K. in Japan.
While leading the Japanese business, he also served as vice chairman of EFPIA Japan and as a director of the Japan Pharmaceutical Manufacturers Association. In October 2017 he became executive vice president for AstraZeneca’s Oncology Business Unit.
His portfolio combines global commercial strategy with marketing, sales, medical affairs and market access. His other AstraZeneca work has included leading North American inclusion and diversity strategy and serving as executive lead for its Health Equity Advisory Council. Caris Life Sciences appointed him to its board in August 2024; its 2026 proxy records that role alongside his AstraZeneca career.
Bachelor of Arts — Georgetown University — Government.